-
1 Comment
KYORIN Holdings, Inc is currently in a long term downtrend where the price is trading 7.7% below its 200 day moving average.
From a valuation standpoint, the stock is 98.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.0.
KYORIN Holdings, Inc's total revenue sank by 10.2% to $27B since the same quarter in the previous year.
Its net income has dropped by 32.6% to $2B since the same quarter in the previous year.
Based on the above factors, KYORIN Holdings, Inc gets an overall score of 1/5.
| Exchange | TSE |
|---|---|
| CurrencyCode | JPY |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| ISIN | JP3247090008 |
| Market Cap | 64B |
|---|---|
| PE Ratio | 18.45 |
| Target Price | 1100 |
| Beta | -0.04 |
| Dividend Yield | 5.2% |
KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells generic drugs in Japan and internationally. The company is also involved in drug discovery and licensing activities. It also offers infectious disease-related products; over-the-counter drug; and generic drugs. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4569.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
